Patient characteristics
| Variables . | N = 2425 . |
|---|---|
| Age, y | |
| Median (range) | 50 (16-74) |
| <50 /≥50 | 1185/1240 |
| Sex, female/male | 1038/1387 |
| PS, 0-1/2-4 | 1970/359 |
| HCT-CI, 0-2/3-/unknown | 1475/213/739 |
| Disease, AML MDS/ALL/NHL/ATL/CML/MM/AA/others | 1234/381/350/128/81/60/61/130 |
| Disease risk, standard/high | 1208/1217 |
| Prior allo-HSCT, N/Y | 2019/406 |
| Conditioning regimen, MAC/RIC | 1171/1146 |
| Donor source, Rel-BM/Rel-PB/UR-BM/CB | 471/422/870/662 |
| HLA disparity, matched/mismatched | 967/1458 |
| Sex mismatch, matched/F to M/M to F | 1180/549 /538 |
| ABO mismatch, matched/major/minor/major-minor | 1060/418/518/227 |
| GVHD prophylaxis, CyA-/FK506-based | 758/1667 |
| Year of HSCT, 2000-2009/2010-2016 | 1147/1278 |
| Follow-up for survivors, median (range), d | 1499 (31-5943) |
| Variables . | N = 2425 . |
|---|---|
| Age, y | |
| Median (range) | 50 (16-74) |
| <50 /≥50 | 1185/1240 |
| Sex, female/male | 1038/1387 |
| PS, 0-1/2-4 | 1970/359 |
| HCT-CI, 0-2/3-/unknown | 1475/213/739 |
| Disease, AML MDS/ALL/NHL/ATL/CML/MM/AA/others | 1234/381/350/128/81/60/61/130 |
| Disease risk, standard/high | 1208/1217 |
| Prior allo-HSCT, N/Y | 2019/406 |
| Conditioning regimen, MAC/RIC | 1171/1146 |
| Donor source, Rel-BM/Rel-PB/UR-BM/CB | 471/422/870/662 |
| HLA disparity, matched/mismatched | 967/1458 |
| Sex mismatch, matched/F to M/M to F | 1180/549 /538 |
| ABO mismatch, matched/major/minor/major-minor | 1060/418/518/227 |
| GVHD prophylaxis, CyA-/FK506-based | 758/1667 |
| Year of HSCT, 2000-2009/2010-2016 | 1147/1278 |
| Follow-up for survivors, median (range), d | 1499 (31-5943) |
CB, cord blood; CyA, cyclosporine A; F to M, female donor to male recipient; M to F, male donor to female recipient; N, no; Rel-BM, related bone marrow; Rel-PB, related peripheral blood stem cell; UR-BM, unrelated bone marrow; Y, yes.